Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
商品番号 : SMB-71342
| 出版社 | BCC Research |
| 出版年月 | 2024年12月 |
| ページ数 | 125 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,650 |
| 種別 | 英文調査報告書 |
Report Highlights
The global market for Alzheimer’s disease therapeutics and diagnostics was valued at $9 billion in 2023. This market is expected to grow from $9.7 billion in 2024 to $19.6 billion by 2029, at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2029.
アルツハイマー病の治療薬および診断薬の世界市場は、2023年に90億ドルと評価されています。この市場は、2024年から2029年までの年間平均成長率（CAGR）15.1%で、2024年の97億ドルから2029年までに196億ドルに成長すると予想されています。
Summary:
Alzheimer’s disease (AD) is a neurodegenerative condition that progresses through a continuum, starting from preclinical stages to mild cognitive and behavioral impairments, and ultimately leading to dementia. The prevalence of AD doubles each decade after ages 65 years. Given the aging population globally, the prevalence of AD is on the rise.
The global market for biomarker tests for AD screening and diagnosis was valued at $5.4 billion in 2023 and is projected to reach $8.8 billion by the end of 2029, growing at a compound annual growth rate (CAGR) of 8.7% through the forecast period. The current landscape of AD diagnosis is advancing rapidly due to improvements in nuclear imaging technology, biomarker research, and an increased focus on early detection. Biomarkers are of enormous use in the diagnosis of AD. They are objective measures, they are reproducible, and they are independent of the clinician’s judgment. Cerebral spinal fluid (CSF) examination, brain imaging using positron emission tomography (PET) scans, and blood/plasma analysis are available for biomarker-based validation of AD diagnosis.
PET imaging and CSF testing are often accurate, but several limitations are attached to these testing methods, which hampers their application as a practical tool for widespread use. PET scans are costly, and CSF is a highly invasive process requiring lumbar puncture. At the time of this publication, the FDA has not approved blood biomarker tests.
Report Scope
This report focuses on the global market for Alzheimer’s disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.
The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used “off-label” to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer’s. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.
An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2023 | ||||||||||||||||
| Forecast period considered | 2024-2029 | ||||||||||||||||
| Base year market size | $9.0 Billion | ||||||||||||||||
| Market size forecast | $19.6 Billion | ||||||||||||||||
| Growth rate | CAGR of 15.1% from 2024 to 2029 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | Diagnostic Test Type, Therapeutics Purpose, Drug Class, Drug Type, Disease Stage, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, and the Rest of the World (RoW) | ||||||||||||||||
| Countries covered | U.S., Canada, Mexico, Germany, the U.K., France, Italy, China and Japan | ||||||||||||||||
| Key Market Drivers |
| ||||||||||||||||
| Companies studied |
| ||||||||||||||||
Report Includes
– 38 data tables and 80 additional tables
– Analyses of the trends in the global market for Alzheimer’s disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029
– Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region
– Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors
– Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments
– Information on products that are currently available for the diagnosis and treatment of Alzheimer’s disease, as well as the promising new drug candidates and diagnostic imaging agents
– An analysis of patents, emerging trends and the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
– Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Alzheimer’s Disease Overview
Alzheimer’s Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Diagnosis of AD
Cognitive Status Testing
Brain Imaging
Lumbar Puncture
Blood-Biomarker Tests
Genetic Testing
Pharmaceutical Treatment of AD
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Growing Incidence of AD
High Unmet Need
Growing Focus on Biomarkers in Diagnosis and Drug Development
Increasing Public and Private investment in Neuroscience
Growing Public Awareness and Early Diagnosis
Large Number of Drugs in Late-Stage Clinical Trials
Market Restraints
High Costs of Diagnostics and Novel Therapies
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development
Chapter 4 Emerging Technologies and Developments
Emerging Technologies/Trends
Blood Tests for AD Screening and Diagnosis
Disease Modifying Small-Molecule Drugs
Re-purposed Drugs
AI and Machine Learning
Pipeline Analysis
Overview
Therapeutic Purpose Type
Novel AD Therapeutics in Development in Phase 3
By Target Type
By Disease State
Novel PET Radiotracers in Development
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Test Type
AD Biomarker Tests Market, by Test Type
AD Therapeutics Market, by Therapeutic Purpose
AD Therapeutics Market, by Drug Class
AD Therapeutics Market, by Drug Type
AD Therapeutics Market, by Disease Stage
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Intelligence
AD Therapeutics
Alzheimer’s Generic Drug Market
Alzheimer’s Branded Drug Market
Donepezil
Rivastigmine
Galantamine
Memantine
Combination Therapy (Memantine and Donepezil)
AD Diagnostics
Overview
Product Launches/Approvals in the AD Diagnostics Market
Chapter 7 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ALPHA COGNITION
ALZPATH INC.
AUROBINDO PHARMA
BIOGEN
C2N DIAGNOSTICS
CORIUM LLC.
DIADEM SRL
EISAI CO. LTD.
HOFFMANN-LA ROCHE LTD.
H.U. GROUP HOLDINGS INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LILLY
OTSUKA HOLDINGS CO. LTD.
QUEST DIAGNOSTICS INC.
List of Tables
Summary Table : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 1 : Brain Imaging Technologies and Application in the Alzheimer’s Context
Table 2 : Common Methods for AD Detection
Table 3 : Key Clinical Biomarkers Used in the Diagnosis of AD
Table 4 : NIH Funding Estimates for Alzheimer’s Disease Research, 2017–2024
Table 5 : Selected AD Biomarker-Focused Consortia
Table 6 : Recent Therapeutic Programs Ceased Due to Failure in Clinical Trials
Table 7 : Selected Blood Tests in Development for AD Screening/Diagnosis
Table 8 : Disease Modifying Small Molecules AD Drug Candidates in Phase 3 Clinical Trials
Table 9 : Disease Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 10 : Treatments for AD-Related Neuropsychiatric and Behavioral Symptoms in Phase 3 Clinical Trials
Table 11 : Cognitive Enhancer AD Drug Candidates in Phase 3 Clinical Trials
Table 12 : Radiopharmaceuticals for CNS Imaging in Clinical Development
Table 13 : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 14 : Comparison of Biomarker Tests
Table 15 : FDA-Approved PET Radiopharmaceuticals for AD Diagnosis
Table 16 : CSF-Based IVD Tests for AD
Table 17 : Blood Tests for AD Diagnosis
Table 18 : Global Market for AD Biomarker Tests, by Test Type, Through 2029
Table 19 : FDA-Approved Drugs to Treat Cognitive Symptoms of AD
Table 20 : FDA-Approved Drugs to Treat Non-Cognitive Symptoms of AD
Table 21 : Global Market for AD Therapeutics, by Therapeutic Purpose, Through 2029
Table 22 : FDA-Approved AChEIs
Table 23 : FDA-Approved Anti-Amyloid Antibodies
Table 24 : Selected Anti-Inflammatory and Neuroprotective Agents in Phase 3 Clinical Trials
Table 25 : Global Market for AD Therapeutics, by Drug Class, Through 2029
Table 26 : Anti-Amyloid Drugs in Phase 3 Clinical Development
Table 27 : Neurotransmitter Modulars in Clinical Trials Phase 3
Table 28 : Global Market for AD Therapeutics, by Drug Type, Through 2029
Table 29 : Patent Information for AD Drugs
Table 30 : Number of Companies with Active FDA Approval to Market AD drugs in the U.S.
Table 31 : FDA-Approved AD Drugs and Their Indications
Table 32 : Global Market for AD Therapeutics, by Disease Stage, Through 2029
Table 33 : Global Market for AD Therapeutics and Diagnostics, by Region, Through 2029
Table 34 : North American Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 35 : North American Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 36 : U.S. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 37 : Canadian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 38 : Mexican Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 39 : European Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 40 : Europe Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 41 : German Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 42 : French Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 43 : U.K. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 44 : Italian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 45 : Rest of European Countries’ Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 46 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 47 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 48 : Chinese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 49 : Japanese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 50 : Rest of Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 51 : RoW Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 52 : Key Companies in the U.S. Alzheimer’s Generic Drug Market
Table 53 : Commercially Available FDA-Approved Branded AD Drugs
Table 54 : Companies with Active FDA Approval to Market Donepezil in the U.S.
Table 55 : Companies with Active FDA Approval to Market Rivastigmine in the U.S.
Table 56 : Companies with Active FDA Approval to Market Galantamine in U.S.
Table 57 : Companies with Active FDA Approval to Market Memantine in the U.S.
Table 58 : Companies with Active FDA Approval to Market Combination Therapy (Memantine and Donepezil) in the U.S.
Table 59 : Selected Product Approvals/Launches in the AD Diagnostics Market, 2022–2024
Table 60 : Information Sources in this Report
Table 61 : Abbreviations Used in This Report
Table 62 : AbbVie Inc.: Company Snapshot
Table 63 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 64 : AbbVie Inc.: Product Portfolio
Table 65 : AbbVie Inc.: News/Key Developments, 2024
Table 66 : Alpha Cognition: Company Snapshot
Table 67 : Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 68 : Alpha Cognition: Product Portfolio
Table 69 : Alpha Cognition: News/Key Developments, 2024
Table 70 : ALZpath Inc.: Company Snapshot
Table 71 : ALZpath Inc.: Product Portfolio
Table 72 : ALZpath Inc.: News/Key Developments, 2023 and 2024
Table 73 : Aurobindo Pharma: Company Snapshot
Table 74 : Aurobindo Pharma: Financial Performance, FY 2022 and 2023
Table 75 : Aurobindo Pharma: Product Portfolio
Table 76 : Aurobindo Pharma: News/Key Developments, 2023
Table 77 : Biogen: Company Snapshot
Table 78 : Biogen: Financial Performance, FY 2022 and 2023
Table 79 : Biogen: Product Portfolio
Table 80 : Biogen: News/Key Developments, 2023 and 2024
Table 81 : C₂N Diagnostics: Company Snapshot
Table 82 : C₂N Diagnostics: Product Portfolio
Table 83 : C₂N Diagnostics: News/Key Developments, 2023 and 2024
Table 84 : Corium LLC.: Company Snapshot
Table 85 : Corium LLC.: Product Portfolio
Table 86 : Corium LLC.: News/Key Developments, 2022 and 2023
Table 87 : Diadem srl: Company Snapshot
Table 88 : Diadem srl: Product Portfolio
Table 89 : Diadem srl: News/Key Developments, 2022 and 2023
Table 90 : Eisai Co. Ltd.: Company Snapshot
Table 91 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 92 : Eisai Co. Ltd.: Product Portfolio
Table 93 : Eisai Co. Ltd.: News/Key Developments, 2022–2024
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
Table 98 : H.U. Group Holdings Inc.: Company Snapshot
Table 99 : H.U. Group Holdings Inc.: Financial Performance, FY 2022 and 2023
Table 100 : H.U. Group Holdings Inc.: Product Portfolio
Table 101 : H.U. Group Holdings Inc.: News/Key Developments, 2022–2024
Table 102 : Laboratory Corporation of America Holdings: Company Snapshot
Table 103 : Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
Table 104 : Laboratory Corporation of America Holdings: Product Portfolio
Table 105 : Laboratory Corporation of America Holdings: News/Key Developments, 2022–2024
Table 106 : Lilly: Company Snapshot
Table 107 : Lilly: Financial Performance, FY 2022 and 2023
Table 108 : Lilly: Product Portfolio
Table 109 : Lilly: News/Key Developments, 2024
Table 110 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 111 : Otsuka Holdings Co. Ltd: Financial Performance, FY 2022 and 2023
Table 112 : Otsuka Holdings Co. Ltd: Product Portfolio
Table 113 : Otsuka Holdings Co. Ltd: News/Key Developments, 2023 and 2024
Table 114 : Quest Diagnostics Inc.: Company Snapshot
Table 115 : Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
Table 116 : Quest Diagnostics Inc.: Product Portfolio
Table 117 : Quest Diagnostics Inc.: News/Key Developments, 2022–2024
List of Figures
Summary Figure : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 1 : Hypothetical Models for Progression of Alzheimer’s Disease
Figure 2 : Market Dynamics of Alzheimer’s Disease Therapeutics and Diagnostics
Figure 3 : Breakdown of Global Aging Population (65 or Older) with Alzheimer’s-Associated Dementia, by Age Group, 2023
Figure 4 : Breakdown of Dementia Cases in Japan, by Disease Type
Figure 5 : Alzheimer’s and Related Dementia Research Funding at the NIH, 2013–2023
Figure 6 : Potential Use of Blood-Based Biomarkers in Primary Care
Figure 7 : Novel Industry-Sponsored AD Therapeutic Agents in Clinical Development, by Clinical Trial Phase
Figure 8 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Type
Figure 9 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Subtype
Figure 10 : Number of AD Clinical Trials for Most Common Targets, by Phase, as of Oct. 2024
Figure 11 : Share of Active Clinical Trials for AD, by Disease State, as of Oct. 2024
Figure 12 : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 13 : Global Market Shares of AD Biomarker Tests, by Test Type, 2023
Figure 14 : Global Market Shares of AD Therapeutics, by Therapeutic Purpose, 2023
Figure 15 : Global Market Shares of AD Therapeutics, by Drug Class, 2023
Figure 16 : Global Market Shares of AD Therapeutics, by Drug Type, 2023
Figure 17 : Alzheimer’s Disease (AD) Continuum
Figure 18 : Global Market Shares of AD Therapeutics, by Disease Stage, 2023
Figure 19 : Global Market for AD Therapeutics and Diagnostics, by Region, 2021–2029
Figure 20 : Global Market Shares of AD Therapeutics and Diagnostics, by Region, 2023
Figure 21 : North American Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 22 : North American Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 23 : European Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 24 : European Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 25 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 26 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 27 : RoW Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 28 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 29 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 30 : Aurobindo Pharma: Revenue Share, by Business Unit, FY 2023
Figure 31 : Aurobindo Pharma: Revenue Share, by Country/Region, FY 2023
Figure 32 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Eisai Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 37 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 38 : Laboratory Corporation of America Holdings: Revenue Share, by Business Unit, FY 2023
Figure 39 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 40 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 41 : Otsuka Holdings Co. Ltd: Revenue Share, by Business Unit, FY 2023
Figure 42 : Otsuka Holdings Co. Ltd: Revenue Share, by Country/Region, FY 2023
Figure 43 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2023
BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。
ライセンス別価格表
2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
新価格表
ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 4,650 | USD 5,580 | USD 6,696 | USD 8,035 |
ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,950 | USD 3,540 | USD 4,248 | USD 5,098 |
ライセンスタイプ3
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 2,500 | USD 3,000 | USD 3,600 | USD 4,320 |
旧価格表
旧ライセンスタイプ1
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 5,500 | USD 6,600 | USD7.920 | USD 9,504 |
旧ライセンスタイプ2
| シングルユーザ | 2-5ユーザ | サイト | エンタープライズ |
| USD 3,500 | USD 4,200 | USD 5,040 | USD 6,048 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- 2-5ライセンス
- 同一企業内5名までレポートファイルのご利用が可能です。
- サイトライセンス
- 同一企業同住所内でレポートファイルのご利用が可能です。
- エンタープライズライセンス
- 同一企業内人数無制限でレポートファイルのご利用が可能です。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後3営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
- 免疫療法薬の世界市場 2025-11-12
- 農業におけるAIの世界市場 2025-11-10
- 固体酸化物形燃料電池の技術と世界市場 2025-11-07
- 世界の電気アーク炉市場 2025-11-07
